中华临床感染病杂志
中華臨床感染病雜誌
중화림상감염병잡지
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
2011年
1期
25-28
,共4页
彭春仙%吴芬芝%郑晓燕%沈丹%姚航平%范剑
彭春仙%吳芬芝%鄭曉燕%瀋丹%姚航平%範劍
팽춘선%오분지%정효연%침단%요항평%범검
淋巴瘤%拉米夫定%肝炎病毒,乙型%乙型肝炎核心抗体
淋巴瘤%拉米伕定%肝炎病毒,乙型%乙型肝炎覈心抗體
림파류%랍미부정%간염병독,을형%을형간염핵심항체
Lymphoma%Lamivudine%Hepatitis virus B%Hepatitis B core antibody
目的 探讨拉米夫定对乙型肝炎核心抗体(抗-HBc)阳性淋巴瘤患者化疗后病毒激活和肝功能损害的预防作用.方法 79例HBsAg(-)而抗-HBc(+)的淋巴瘤患者分为拉米夫定治疗组(37例)和对照组(42例).两组患者均进行联合化疗,期间观察肝功能损害和HBV激活情况,并用SSPS 13.0软件进行统计学分析.结果 预防性应用拉米夫定治疗的37例患者中,化疗后出现肝功能损害Ⅰ～Ⅱ期11例(29.7%),Ⅲ～Ⅳ期2例(5.4%),HBV激活2例(5.4%),而且这2例患者均出现HBV YMDD基因变异.42例化疗时未进行抗病毒治疗的患者中,化疗后出现肝功能损害Ⅰ～Ⅱ期19例(45.2%),Ⅲ～Ⅳ期7例(16.7%),HBV激活12例(28.6%),与拉米夫定治疗组比较差异均具有统计学意义(χ2值分别为79.0、8.7和79.0,P值＜0.05或＜0.01).结论 HBsAg(-)而抗-HBc(+)淋巴瘤患者进行化疗时预防性应用拉米夫定可以减少肝脏损害的发生和HBV的激活.
目的 探討拉米伕定對乙型肝炎覈心抗體(抗-HBc)暘性淋巴瘤患者化療後病毒激活和肝功能損害的預防作用.方法 79例HBsAg(-)而抗-HBc(+)的淋巴瘤患者分為拉米伕定治療組(37例)和對照組(42例).兩組患者均進行聯閤化療,期間觀察肝功能損害和HBV激活情況,併用SSPS 13.0軟件進行統計學分析.結果 預防性應用拉米伕定治療的37例患者中,化療後齣現肝功能損害Ⅰ～Ⅱ期11例(29.7%),Ⅲ～Ⅳ期2例(5.4%),HBV激活2例(5.4%),而且這2例患者均齣現HBV YMDD基因變異.42例化療時未進行抗病毒治療的患者中,化療後齣現肝功能損害Ⅰ～Ⅱ期19例(45.2%),Ⅲ～Ⅳ期7例(16.7%),HBV激活12例(28.6%),與拉米伕定治療組比較差異均具有統計學意義(χ2值分彆為79.0、8.7和79.0,P值＜0.05或＜0.01).結論 HBsAg(-)而抗-HBc(+)淋巴瘤患者進行化療時預防性應用拉米伕定可以減少肝髒損害的髮生和HBV的激活.
목적 탐토랍미부정대을형간염핵심항체(항-HBc)양성림파류환자화료후병독격활화간공능손해적예방작용.방법 79례HBsAg(-)이항-HBc(+)적림파류환자분위랍미부정치료조(37례)화대조조(42례).량조환자균진행연합화료,기간관찰간공능손해화HBV격활정황,병용SSPS 13.0연건진행통계학분석.결과 예방성응용랍미부정치료적37례환자중,화료후출현간공능손해Ⅰ～Ⅱ기11례(29.7%),Ⅲ～Ⅳ기2례(5.4%),HBV격활2례(5.4%),이차저2례환자균출현HBV YMDD기인변이.42례화료시미진행항병독치료적환자중,화료후출현간공능손해Ⅰ～Ⅱ기19례(45.2%),Ⅲ～Ⅳ기7례(16.7%),HBV격활12례(28.6%),여랍미부정치료조비교차이균구유통계학의의(χ2치분별위79.0、8.7화79.0,P치＜0.05혹＜0.01).결론 HBsAg(-)이항-HBc(+)림파류환자진행화료시예방성응용랍미부정가이감소간장손해적발생화HBV적격활.
Objective To evaluate the effectiveness of lamivudine in preventing liver damages and HBV DNA reactivation in anti-HBc positive lymphoma patients after chemotherapy.Methods Seventy-nine lymphoma patients who were negative in HBsAg and positive in anti-HBc were enrolled and were divided into lamivudine group (n=37) and control group (n=42).Both groups received chemotherapy.Liver damages and HBV reactivation were observed, and the data were analyzed with software SPSS 13.0.Results In lamivudine group, liver damages Ⅰ or Ⅱ was observed in 11 patients (11/37, 29.7%), and liver damages Ⅲ or Ⅳ was observed in 2 (2/37, 5.4%); two patients (2/37, 5.4%) developed HBV reactivation, and both of them had HBV YMDD mutations.In control group, 19 (19/42, 45.2%) patients experienced liver damages Ⅰ or Ⅱ, 7 (7/42, 16.7%) experienced liver damages Ⅲ or Ⅳ; 12 (12/42, 28.6%) patients experienced HBV reactivation, the differences between the two groups were of statistical significance (χ2=79.0, 8.7 and 79.0, P ＜ 0.05 or ＜ 0.01).Conclusion Lamivudine can reduce liver damages and HBV reactivation in HBsAg negative and anti-HBc positive patients with lymphoma during chemotherapy.
